|
Thyroid carcinoma
|
0.500 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Thyroid carcinoma
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
|
Thyroid carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
1alpha,25-Dihydroxyvitamin D3 targets PTEN-dependent fibronectin expression to restore thyroid cancer cell adhesiveness.
|
15890670 |
2005 |
|
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PTEN mutations have been implicated in the development of a variety of human neoplasia, including high-grade glioblastoma, prostate, breast, endometrial, and thyroid carcinoma.
|
10910075 |
2000 |
|
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PTEN, a dual-phosphatase tumor suppressor, is inactivated in Cowden syndrome (CS), characterized by high risk of breast and thyroid cancer, and in variety of sporadic cancers.
|
16436456 |
2006 |
|
Thyroid carcinoma
|
0.500 |
PosttranslationalModification
|
disease |
BEFREE |
PTEN promoter methylation in sporadic thyroid carcinomas.
|
16487009 |
2006 |
|
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PTEN knockdown in thyroid cancer cell lines stabilized intracellular NIS protein by promoting an interaction with NIS-LARG (leukemia-associated RhoA guanine exchange factor).
|
30217930 |
2018 |
|
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A total of 32 of 225 PTEN mutation+ patients (14%) had thyroid cancer: 52% papillary, 28% follicular-variant papillary, 14% follicular, and 6% anaplastic.
|
23158187 |
2012 |
|
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
After co-culture with TC cell lines, TC-induced macrophages showed significantly increased production of cytokines in both patients and controls, especially after co-culture with a PTEN-deficient TC cell line; these effects were abolished after use of rapamycin or a lactate transport blocker.
|
30670777 |
2019 |
|
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
At the present time, no study has been undertaken to consider thyroid cancer treatment via FOXOs and PTEN targeting.
|
26597586 |
2016 |
|
Thyroid carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Because in most of the thyroid carcinomas, DeltaNp73alpha is upregulated, whereas PTEN expression down regulated, we investigated whether DeltaNp73alpha may influence PTEN expression in this cell model.
|
19173293 |
2009 |
|
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Children presenting with thyroid cancer should be tested for PTEN mutations.
|
21956414 |
2011 |
|
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline PTEN mutations cause 85% of Cowden syndrome (CS), characterized by a high risk of breast and thyroid cancers, and 65% of Bannayan-Riley-Ruvalcaba syndrome (BRRS), characterized by lipomatosis, hemangiomas and speckled penis.
|
17405772 |
2007 |
|
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline phosphatase and tensin homolog (PTEN) mutations cause Cowden syndrome (CS), associated with breast and thyroid cancers.
|
20600018 |
2010 |
|
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in PTEN, encoding a dual-specificity phosphatase on 10q23.3, cause Cowden syndrome (CS), which is characterized by a high risk of breast and thyroid cancers.
|
10514407 |
1999 |
|
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in PTEN cause Cowden syndrome (CS), which is characterized by multiple hamartomas and a high risk of breast and thyroid cancers.
|
11021816 |
2000 |
|
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in the PTEN gene, which cause Cowden syndrome, are known to be one of the genetic factors for primary thyroid and breast cancers; however, PTEN mutations are found in only a small subset of research participants with non-syndrome breast and thyroid cancers.
|
26699384 |
2016 |
|
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome.
|
9140396 |
1997 |
|
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Germline variants in SDHB/C/D (SDHx) genes account for subsets of CS/CS-like cases, conferring a higher risk of breast and thyroid cancers over those with only germline PTEN mutations.
|
25694510 |
2015 |
|
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
HMGB1-Induced Cross Talk between PTEN and miRs 221/222 in Thyroid Cancer.
|
26106610 |
2015 |
|
Thyroid carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our data define a novel mechanism of PI3K/AKT hyperactivation and outline a regulatory role for miR-146b in suppressing PTEN expression, a frequent observation in thyroid cancer.
|
29353884 |
2018 |
|
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this study, we confirm that PTEN mutations in sporadic thyroid cancer are infrequent as we found one point mutation and one heterozygous deletion of PTEN gene in 26 tumors and eight cell lines screened.
|
10918569 |
2000 |
|
Thyroid carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Interestingly, KLLN-associated risk of thyroid cancer appears to be gender and PTEN status dependent.
|
25669429 |
2015 |
|
Thyroid carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Moreover, germline mutation of PTEN leads to the development of the related hereditary cancer predisposition syndromes, Cowden disease, and Bannayan-Zonana syndrome, wherein breast and thyroid cancer incidence is elevated.
|
15254063 |
2004 |